title: Inhibition of macrophage inflammatory cytokine secretion by chylomicron remnants is dependent on their uptake by the low density lipoprotein receptor.
abstract: Secretion of pro-inflammatory chemokines and cytokines by macrophages is a contributory factor in the pathogenesis of atherosclerosis. In this study, the effects of chylomicron remnants (CMR), the lipoproteins which transport dietary fat in the blood, on the production of pro-inflammatory chemokine and cytokine secretion by macrophages was investigated using CMR-like particles (CRLPs) together with THP-1 macrophages or primary human macrophages (HMDM). Incubation of CRLPs or oxidized CRLPs (oxCRLPs) with HMDM or THP-1 macrophages for up to 24h led to a marked decrease in the secretion of the pro-inflammatory chemokine monocyte chemoattractant protein-1 (MCP-1) and the pro-inflammatory cytokines tumour necrosis factor-α (TNF-α), interleukin (IL)-6 and IL-1β (-50-90%), but these effects were reduced or abolished when CRLPs protected from oxidation by incorporation of the antioxidant drug, probucol, (pCRLPs) were used. In macrophages transfected with siRNA targeted to the low density lipoprotein receptor (LDLr), neither CRLPs nor pCRLPs had any significant effect on chemokine/cytokine secretion, but in cells transfected with siRNA targeted to the LDLr-related protein 1 (LRP1) both types of particles inhibited secretion to a similar extent to that observed with CRLPs in mock transfected cells. These findings demonstrate that macrophage pro-inflammatory chemokine/cytokine secretion is down-regulated by CMR, and that these effects are positively related to the lipoprotein oxidative state. Furthermore, uptake via the LDLr is required for the down-regulation, while uptake via LRP1 does not bring about this effect. Thus, the receptor-mediated route of uptake of CMR plays a crucial role in modulating their effects on inflammatory processes in macrophages.
authors.affiliation: Department of Veterinary Basic Sciences, The Royal Veterinary College, London, UK. vgraham@rvc.ac.uk
authors.forename: Valerie S
authors.initials: VS
authors.lastname: Graham
authors.forename: Paola
authors.initials: P
authors.lastname: Di Maggio
authors.forename: Sandra
authors.initials: S
authors.lastname: Armengol
authors.forename: Charlotte
authors.initials: C
authors.lastname: Lawson
authors.forename: Caroline P D
authors.initials: CP
authors.lastname: Wheeler-Jones
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Botham
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D000975:Antioxidants / Q000494:pharmacology; D002460:Cell Line; D053298:Chylomicron Remnants / Q000378:metabolism* / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism*; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D026503:Low Density Lipoprotein Receptor-Related Protein-1 / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism*; D011341:Probucol / Q000494:pharmacology; D011973:Receptors, LDL / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D000975:Antioxidants; D053298:Chylomicron Remnants; D016207:Cytokines; D018836:Inflammation Mediators; C475476:LRP1 protein, human; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D011973:Receptors, LDL; D011341:Probucol